[go: up one dir, main page]

UA94452C2 - Гуманизированные моноклональные антитела к фактору роста гепатоцитов - Google Patents

Гуманизированные моноклональные антитела к фактору роста гепатоцитов

Info

Publication number
UA94452C2
UA94452C2 UAA200812789A UAA200812789A UA94452C2 UA 94452 C2 UA94452 C2 UA 94452C2 UA A200812789 A UAA200812789 A UA A200812789A UA A200812789 A UAA200812789 A UA A200812789A UA 94452 C2 UA94452 C2 UA 94452C2
Authority
UA
Ukraine
Prior art keywords
growth factor
hepatocyte growth
monoclonal antibodies
humanized monoclonal
pharmaceutical composition
Prior art date
Application number
UAA200812789A
Other languages
English (en)
Ukrainian (uk)
Inventor
Киунг Дзин Ким
Лихун Ван
Ханджил Парк
Максимильяно Васкес
Original Assignee
ГЕЛЕКСИ БАЙОТЕК, ЭлЭлСи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ГЕЛЕКСИ БАЙОТЕК, ЭлЭлСи filed Critical ГЕЛЕКСИ БАЙОТЕК, ЭлЭлСи
Publication of UA94452C2 publication Critical patent/UA94452C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Изобретение относится к гуманизированному нейтрализующему моноклональному антителу против фактора роста гепатоцитов, фармацевтической композиции, которая содержит его, и применения для лечения, которое включает введение такой фармацевтической композиции пациенту.
UAA200812789A 2006-04-01 2007-03-28 Гуманизированные моноклональные антитела к фактору роста гепатоцитов UA94452C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US78824306P 2006-04-01 2006-04-01

Publications (1)

Publication Number Publication Date
UA94452C2 true UA94452C2 (ru) 2011-05-10

Family

ID=38564195

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200812789A UA94452C2 (ru) 2006-04-01 2007-03-28 Гуманизированные моноклональные антитела к фактору роста гепатоцитов

Country Status (25)

Country Link
US (3) US7632926B2 (ru)
EP (2) EP2016162B1 (ru)
JP (1) JP5312315B2 (ru)
KR (1) KR101516289B1 (ru)
CN (2) CN103172736A (ru)
AR (1) AR059922A1 (ru)
AU (1) AU2007233242B2 (ru)
BR (1) BRPI0709932A2 (ru)
CA (1) CA2645358C (ru)
CO (1) CO6140067A2 (ru)
CR (1) CR10308A (ru)
ES (1) ES2465668T3 (ru)
GE (1) GEP20125517B (ru)
IL (1) IL194221A (ru)
MA (1) MA30382B1 (ru)
MX (1) MX2008012619A (ru)
MY (1) MY145042A (ru)
NO (1) NO20084539L (ru)
NZ (1) NZ571132A (ru)
PE (1) PE20080008A1 (ru)
RU (1) RU2461570C2 (ru)
TW (1) TWI417300B (ru)
UA (1) UA94452C2 (ru)
WO (1) WO2007115049A2 (ru)
ZA (1) ZA200807903B (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040208876A1 (en) * 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
CN103755807A (zh) 2003-07-18 2014-04-30 安姆根有限公司 肝细胞生长因子的特异性结合物
BRPI0611009A2 (pt) * 2005-06-02 2010-08-10 Galaxy Biotech Llc usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos
JP4686634B2 (ja) 2006-06-02 2011-05-25 アベオ ファーマシューティカルズ， インコーポレイテッド 肝細胞成長因子（ｈｇｆ）結合蛋白質
EP2029627B1 (en) 2006-06-02 2011-11-16 Aveo Pharmaceuticals, Inc. Hepatocyte growth factor (hgf) binding proteins
WO2007145840A2 (en) * 2006-06-13 2007-12-21 Oncomed Pharmaceuticals, Inc. Compositions and methods for diagnosing and treating cancer
JP5618544B2 (ja) 2007-01-24 2014-11-05 オンコメッドファーマシューティカルズ インコーポレイテッド 癌の診断および処置のための組成物および方法
CN102014913A (zh) * 2008-03-06 2011-04-13 健泰科生物技术公司 C-met和egfr拮抗剂的联合疗法
EP2636513B1 (en) * 2008-04-10 2014-08-27 Stratasys Ltd. System and method for three dimensional model printing
US20110217294A1 (en) * 2008-04-11 2011-09-08 Daniel Fults Combination of hgf inhibitor and hedgehog inhibitor to treat cancer
PE20091714A1 (es) * 2008-04-11 2009-11-15 Galaxy Biotech Llc Combinacion del inhibidor hgf y el agonista pten
PE20091827A1 (es) * 2008-04-11 2009-11-20 Galaxy Biotech Llc Combinacion del inhibidor hgf y el inhibidor egf para el tratamiento del cancer
JP5699075B2 (ja) * 2008-05-14 2015-04-08 アムジエン・インコーポレーテツド 癌の治療のためのｖｅｇｆ（ｒ）阻害剤および肝細胞増殖因子（ｃ−ｍｅｔ）阻害剤との組合せ
AU2009255305B2 (en) 2008-05-29 2014-10-30 Galaxy Biotech, Llc Monoclonal antibodies to basic fibroblast growth factor
US9132189B2 (en) 2008-07-08 2015-09-15 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
NZ590127A (en) 2008-07-08 2012-11-30 Oncomed Pharm Inc Notch1 receptor binding agents and methods of use thereof
DK2842573T3 (en) 2008-11-07 2017-10-30 Galaxy Biotech Llc Monoclonal antibodies to fibroblast growth factor receptor 2
WO2010071208A1 (ja) 2008-12-19 2010-06-24 武田薬品工業株式会社 抗体の精製方法
US20120052064A1 (en) 2009-04-17 2012-03-01 Yuuki Ito Anti-hgf antibody combinational cancer therapies
TW201106971A (en) * 2009-05-28 2011-03-01 Glaxo Group Ltd Antigen-binding proteins
AU2011205316B2 (en) 2010-01-13 2015-05-28 Oncomed Pharmaceuticals, Inc. Notch1 binding agents and methods of use thereof
US9068011B2 (en) 2010-03-10 2015-06-30 Genmab A+S Monoclonal antibodies against c-Met
EP2588107A1 (en) 2010-07-01 2013-05-08 Takeda Pharmaceutical Company Limited COMBINATION OF A cMET INHIBITOR AND AN ANTIBODY TO HGF AND/OR cMET
WO2012044577A1 (en) 2010-09-27 2012-04-05 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases
AU2011333738A1 (en) 2010-11-24 2013-07-11 Glaxo Group Limited Multispecific antigen binding proteins targeting HGF
KR20140067052A (ko) 2011-09-09 2014-06-03 암젠 인코퍼레이티드 식도암 및 위암 환자들에서 항-간세포 성장 인자（“ｈｇｆ”） 항체들의 유효성을 예측하기 위한 ｃ―ｍｅｔ 단백질의 용도
WO2013152252A1 (en) 2012-04-06 2013-10-10 OSI Pharmaceuticals, LLC Combination anti-cancer therapy
US20150157619A1 (en) 2012-07-10 2015-06-11 Takeda Pharmaceutical Company Limited Pharmaceutical preparation for injection
US9931400B2 (en) 2012-09-12 2018-04-03 Samsung Electronics Co., Ltd. Method of combination therapy for prevention or treatment of c-Met or angiogenesis factor induced diseases
US9732150B2 (en) 2013-03-14 2017-08-15 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
US9062104B2 (en) 2013-03-14 2015-06-23 Alderbio Holdings Llc Therapeutic use of antibodies to HGF
EP2964673A4 (en) * 2013-03-14 2017-02-22 Alder Biopharmaceuticals, Inc. Antibodies to hgf and compositions containing
MX2016012285A (es) 2014-03-24 2017-01-23 Genentech Inc Tratamiento de cáncer con antagonista de c-met y correlación de estos con la expresión de hgf.
CN109195626B (zh) 2015-10-30 2022-09-13 银河生物技术有限责任公司 结合死亡受体4和死亡受体5的抗体
KR102812377B1 (ko) 2016-03-01 2025-05-23 이섬 리서치 디벨러프먼트 컴파니 오브 더 히브루 유니버시티 오브 예루살렘 엘티디. 인간 폴리오바이러스 수용체(ｐｖｒ)에 특이적인 항체
WO2021028081A1 (en) 2019-08-12 2021-02-18 Interna Technologies B.V. New treatments involving mirna-193a
AU2021227002A1 (en) 2020-02-28 2022-09-15 Interna Technologies B.V. miRNA-193a for promoting immunogenic cell death
CN113980129B (zh) * 2021-01-15 2023-07-28 东大生物技术(苏州)有限公司 一组il-11单克隆抗体及其医药用途
CN119285785B (zh) * 2024-09-26 2025-04-18 武汉奥科博泰生物科技有限公司 一种抗d-二聚体单克隆抗体及其应用

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2564486B2 (ja) * 1986-07-14 1996-12-18 修治 橋本 肝細胞増殖因子
EP0307434B2 (en) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Altered antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
ES2284161T3 (es) 1990-01-12 2007-11-01 Amgen Fremont Inc. Generacion de anticuerpos xenogenicos.
GB9009548D0 (en) 1990-04-27 1990-06-20 Celltech Ltd Chimeric antibody and method
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2109602C (en) 1990-07-10 2002-10-01 Gregory P. Winter Methods for producing members of specific binding pairs
WO1993012227A1 (en) 1991-12-17 1993-06-24 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
DE122004000008I1 (de) * 1991-06-14 2005-06-09 Genentech Inc Humanisierter Heregulin Antikörper.
US6498144B1 (en) * 1993-10-18 2002-12-24 North Shore - Long Island Jewish Research Institute Use of scatter factor to enhance angiogenesis
US5837676A (en) * 1993-10-18 1998-11-17 Long Island Jewish Medical Center Use of scatter factor to enhance angiogenesis
US5707624A (en) * 1994-06-03 1998-01-13 The Regents Of The University Of Michigan Treatment of Kaposi's sarcoma by inhibition of scatter factor
US5686292A (en) * 1995-06-02 1997-11-11 Genentech, Inc. Hepatocyte growth factor receptor antagonist antibodies and uses thereof
US6214344B1 (en) * 1995-06-02 2001-04-10 Genetech, Inc. Hepatocyte growth factor receptor antagonists and uses thereof
US5646036A (en) * 1995-06-02 1997-07-08 Genentech, Inc. Nucleic acids encoding hepatocyte growth factor receptor antagonist antibodies
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
EP0922102B1 (en) * 1996-07-03 2010-04-21 Genentech, Inc. Hepatocyte growth factor receptor agonists and uses thereof
EP1183275B1 (en) * 1999-05-17 2006-08-09 Avi Biopharma, Inc. Specific antibodies against human chorionic gonadotropin and their use in therapy and diagnostic
WO2001034650A1 (en) 1999-11-09 2001-05-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Heatlh And Human Services Hgf-sf monoclonal antibody combinations
WO2003010282A2 (en) 2001-07-26 2003-02-06 Eli Lilly And Company Interleukin-1 beta antibodies
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
AU2003270118A1 (en) * 2002-08-30 2004-03-19 F. Hoffmann-La Roche Ag Scatter factor/hepatocyte growth factor antagonist nk4 for the treatment of glioma
AU2003900180A0 (en) * 2003-01-16 2003-01-30 Silverbrook Research Pty Ltd Method and apparatus (dam001)
US7220410B2 (en) * 2003-04-18 2007-05-22 Galaxy Biotech, Llc Monoclonal antibodies to hepatocyte growth factor
US20040208876A1 (en) 2003-04-18 2004-10-21 Kim Kyung Jin Monoclonal antibodies to hepatocyte growth factor
EP1636593B9 (en) 2003-06-06 2009-12-16 Genentech, Inc. Modulating the interaction between hgf beta chain and c-met
WO2005007193A2 (en) 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
CN103755807A (zh) 2003-07-18 2014-04-30 安姆根有限公司 肝细胞生长因子的特异性结合物
JP2007506209A (ja) 2003-09-18 2007-03-15 コニンクリユケ フィリップス エレクトロニクス エヌ．ブイ． 情報担体及び情報担体に記憶したデータを読み取るためのシステム
PL2392565T3 (pl) 2003-09-26 2014-08-29 Exelixis Inc Modulatory c-Met i sposoby stosowania
KR100556660B1 (ko) 2003-11-11 2006-03-10 국립암센터 Ｈｇｆ의 중화가능 에피토프 및 이에 결합하는 중화 항체
WO2005079489A2 (en) * 2004-02-17 2005-09-01 Science & Technology Corporation @ Unm Method of treating cancer and identifying novel anti-ancer compounds
US7977345B2 (en) 2004-07-02 2011-07-12 Exelixis, Inc. c-MET modulators and method of use
BRPI0611009A2 (pt) * 2005-06-02 2010-08-10 Galaxy Biotech Llc usos de um anticorpo monoclonal (mab), e, de um anticorpo anti-hgf de neutralização
US7964365B2 (en) 2005-11-08 2011-06-21 The United States of Americam as represented by the Secretary, Department of Health and Human Services Methods for diagnosing and monitoring the progression of cancer
AR059922A1 (es) 2006-04-01 2008-05-07 Galaxy Biotech Llc Anticuerpos monoclonales humanizados para el factor de crecimiento de hepatocitos

Also Published As

Publication number Publication date
BRPI0709932A2 (pt) 2011-08-02
CR10308A (es) 2008-10-27
RU2008143318A (ru) 2010-05-10
WO2007115049A2 (en) 2007-10-11
US20100278815A1 (en) 2010-11-04
MY145042A (en) 2011-12-15
CN101415811A (zh) 2009-04-22
US8628778B2 (en) 2014-01-14
EP2016162A4 (en) 2009-11-11
CO6140067A2 (es) 2010-03-19
CN103172736A (zh) 2013-06-26
KR101516289B1 (ko) 2015-05-07
CA2645358A1 (en) 2007-10-11
EP2476704A3 (en) 2012-07-25
AR059922A1 (es) 2008-05-07
KR20090013777A (ko) 2009-02-05
HK1121489A1 (en) 2009-04-24
AU2007233242B2 (en) 2012-04-26
ES2465668T3 (es) 2014-06-06
MX2008012619A (es) 2008-10-13
EP2476704A2 (en) 2012-07-18
ZA200807903B (en) 2010-03-31
CA2645358C (en) 2015-05-05
TWI417300B (zh) 2013-12-01
US20080019974A1 (en) 2008-01-24
IL194221A (en) 2015-11-30
NO20084539L (no) 2008-10-28
EP2016162A2 (en) 2009-01-21
RU2461570C2 (ru) 2012-09-20
MA30382B1 (fr) 2009-05-04
PE20080008A1 (es) 2008-02-14
GEP20125517B (en) 2012-05-25
EP2016162B1 (en) 2014-04-16
CN101415811B (zh) 2013-01-30
US7632926B2 (en) 2009-12-15
JP5312315B2 (ja) 2013-10-09
JP2009532378A (ja) 2009-09-10
TW200808828A (en) 2008-02-16
US20140335076A1 (en) 2014-11-13
WO2007115049A3 (en) 2008-09-04
AU2007233242A1 (en) 2007-10-11
NZ571132A (en) 2012-05-25

Similar Documents

Publication Publication Date Title
UA94452C2 (ru) Гуманизированные моноклональные антитела к фактору роста гепатоцитов
ZA200609407B (en) Monoclonal antibodies to hepatocyte growth factor
WO2010054265A3 (en) Monoclonal antibodies to fibroblast growth factor receptor 2
TN2010000210A1 (en) Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
UA109633C2 (uk) Антитіло людини проти тканинного фактора
CA2725873A1 (en) Monoclonal antibodies to basic fibroblast growth factor
NZ604007A (en) Monoclonal antibodies against her2 epitope
JO2576B1 (en) Antibodies
UA112743C2 (uk) Терапевтичний dll4-зв'язувальний білок
SI2109623T1 (sl) Zdravljenje raka z anti il protitelesi
MX348579B (es) Composicion farmaceutica para el tratamiento y/o prevencion del cancer.
UA92505C2 (ru) Композиции на основе антитела против cd3
EA200702053A1 (ru) Антитела против cd38 для лечения множественной миеломы
UA90457C2 (ru) Человеческое моноклональное антитело, которое специфически связывается с м-csf человека и блокирует связывание м-csf с с-fms
UA106890C2 (ru) Гуманизированное антитело к cdcp1
MX348581B (es) Composicion farmaceutica para el tratamiento y/o prevencion de cancer.
NZ602166A (en) Antibodies to il-6 and use thereof
IL212633A (en) A monoclonal antibody or its antigen-binding portion, its pharmaceutical preparations and its use in the preparation of cancer drugs
MX2009004532A (es) Composiciones y metodos para unir esfingosina-1-fosfato.
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
EA201100884A1 (ru) Моноклональные антитела анти-rhd
MX2013002718A (es) Composiciones de anticuerpo anti-vegfr-3.
WO2010094981A3 (en) Antibody therapy
TW200740845A (en) Use of anti-MAdCAM antibodies for the treatment of coeliac disease and tropical sprue
UA108207C2 (xx) Високоафінне людське антитіло до людського ангіопоетину-2